[A trial of new protocol of rush immunotherapy with standardized mite antigen].
The objective of the present study was (1) to establish a new protocol of rush immunotherapy (IT) using a purified mite antigen for the treatment of house-dust-mite-sensitive bronchial asthma. Ten adult asthmatics were enrolled in the initial trial which was based on a 7-day protocol using a house-dust antigen, to determine the optimal maintenance dose of mite antigen. No systemic side effects were observed when the antigen dose was lower than 50 AU. Consequently, the duration of rush IT was shortened to 5 days, and the maintenance dose was determined as 50 AU in the new protocol. To confirm its safety, another ten asthmatics were enrolled in a second trial. Rush IT using the new protocol was able to be performed without any systemic side effects in all patients except one who showed urticaria at 40 AU. These results suggest that the 5-day protocol of rush IT using the mite antigen is safe in patients with house-dust-mite-sensitive asthma.
Tabe
K
K
Department of Internal Medicine, Saitama Medical School.
Mizukoshi
T
T
Nishi
Y
Y
Noguchi
T
T
Shuh
S
S
Kobayashi
Y
Y
Shibasaki
M
M
Yamamoto
H
H
Nagata
M
M
Sakamoto
Y
Y
Matsuo
H
H
D000293:Adolescent; D000328:Adult; D000818:Animals; D000941:Antigens / Q000008:administration & dosage*; D001249:Asthma / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000379:methods*; D004391:Dust; D005260:Female; D006801:Humans; D008297:Male; D008925:Mites / Q000276:immunology*
D000941:Antigens; D004391:Dust